Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05368103 · ClinicalTrials.gov registry record · Phase 2
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05368103 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 30 participants.
The verdict
NCT05368103, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.
Interventions
- BIOLOGICAL Daxdilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2024-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05368103
The ClinicalTrials.gov registry entry for NCT05368103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daxdilimab is the first listed.
NCT05368103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05368103 about?
NCT05368103 is a clinical study titled "Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata". The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.
What is the current status of trial NCT05368103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-04-27. Estimated completion is 2024-01-26.
What interventions are being tested in trial NCT05368103?
The interventions under investigation include: Daxdilimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05368103?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.